Compounds > pd 98059
Page last updated: 2024-11-02

pd 98059 and Breast Neoplasms

pd 98059 has been researched along with Breast Neoplasms in 119 studies

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.

Breast Neoplasms: Tumors or cancer of the human BREAST.

Research Excerpts

ExcerptRelevanceReference
" The aim of this study is to investigate whether gemcitabine induces autophagy, and more importantly, whether such autophagy is functional relevant to the therapeutic effects of gemcitabine in breast cancer cells in relation to the ER status."7.83Inhibition of ERα/ERK/P62 cascades induces "autophagic switch" in the estrogen receptor-positive breast cancer cells exposed to gemcitabine. ( Chen, L; Chen, M; Dai, F; He, M; Pan, T; Shen, P; Song, Y; Wan, X; Wang, Q; Xiao, P, 2016)
"Obesity has been associated with an increased risk of postmenopausal breast cancer, which may be due to the expression of leptin."7.80Leptin promotes the proliferation and migration of human breast cancer through the extracellular-signal regulated kinase pathway. ( Sun, KW; Yu, K; Yuan, HJ, 2014)
"In order to explore the synergistic mechanisms of combinatorial treatment using curcumin and mitomycin C (MMC) for breast cancer, MCF-7 breast cancer xenografts were conducted to observe the synergistic effect of combinatorial treatment using curcumin and MMC at various dosages."7.80Synergistic effect of combinatorial treatment with curcumin and mitomycin C on the induction of apoptosis of breast cancer cells: a cDNA microarray analysis. ( Chen, QL; Du, J; Lu, YY; Su, SB; Wang, XF; Zhang, H; Zhou, QM, 2014)
"This study was designed to investigate the role of protein kinase C (PKC) and extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in tamoxifen (TAM)-induced apoptosis and drug resistance in human breast cancer cells."7.78Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells. ( Fang, J; Huang, J; Li, C; Li, Z; Tian, F; Wang, N; Xie, F, 2012)
"To determine the in vitro effects of simultaneously administered LY29400, PD98059, tamoxifen and eicosapentaenoic acid (EPA) on breast cancer cells, and determine their transcutaneous delivery."7.74In vitro effects on MCF-7 breast cancer cells of signal transduction inhibitor/tamoxifen/eicosapentaenoic acid combinations and their simultaneous delivery across skin. ( Davison, Z; Dutkowski, C; Gee, JM; Heard, CM; Nicholson, RI, 2008)
"Tamoxifen (Tam) is widely used in chemotherapy of breast cancer."7.74Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. ( Härkönen, P; Kallio, A; Zheng, A, 2007)
"Despite the success of tamoxifen in treating hormone-responsive breast cancer, its use is limited by the development of resistance to the drug."7.73Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells. ( Kilker, RL; Planas-Silva, MD, 2006)
"We previously reported that the PPARgamma agonist troglitazone (TRO) inhibits proliferation and induces apoptosis in human MCF-7 breast carcinoma cells."7.72Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. ( Blaschke, F; Bruemmer, D; Herle, AJ; Hsueh, WA; Law, RE; Yin, F, 2004)
"Anandamide (ANA) inhibits prolactin- and nerve growth factor (NGF)-induced proliferation of human breast cancer cells by decreasing the levels of the 100 kDa prolactin receptor (PRLr) and the high affinity trk NGF receptor, respectively, and by acting via CB(1)-like cannabinoid receptors."7.70Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. ( De Petrocellis, L; Di Marzo, V; Galve-Roperh, I; Guzmán, M; Melck, D; Rueda, D, 1999)
"In human tamoxifen-resistant breast cancer, our results show a significant correlation between Pin1 overexpression and high levels of LC-3."5.36The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer. ( Cho, HG; Choi, HS; Kang, BS; Khanal, P; Lim, SC; Namgoong, GM; Oh, YK; Shim, JH; Yoo, JC, 2010)
"Human breast cancer MCF-7 cells were exposed to resveratrol (2, 5 and 10 microM)."5.35Resveratrol inhibits heregulin-beta1-mediated matrix metalloproteinase-9 expression and cell invasion in human breast cancer cells. ( Chiang, EP; Sun, YC; Tang, FY, 2008)
"Paclitaxel treatment of parental MCF-7 cells caused a marked inhibition of Raf-1 kinase activity, concomitant with its mobility shift after 18 h exposure."5.32Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells. ( Han, SS; Koh, WS; Lee, M, 2003)
"Human breast cancer cell lines, which express high levels of endogenous Neu receptor, were treated with the anti-Neu antibody, trastuzumab, together with flavopiridol and subject to MTT assay."5.31Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. ( Albanese, C; D'Amico, M; Lee, RJ; Mani, S; Pestell, RG; Wang, C; Wu, K, 2002)
" The aim of this study is to investigate whether gemcitabine induces autophagy, and more importantly, whether such autophagy is functional relevant to the therapeutic effects of gemcitabine in breast cancer cells in relation to the ER status."3.83Inhibition of ERα/ERK/P62 cascades induces "autophagic switch" in the estrogen receptor-positive breast cancer cells exposed to gemcitabine. ( Chen, L; Chen, M; Dai, F; He, M; Pan, T; Shen, P; Song, Y; Wan, X; Wang, Q; Xiao, P, 2016)
"Obesity has been associated with an increased risk of postmenopausal breast cancer, which may be due to the expression of leptin."3.80Leptin promotes the proliferation and migration of human breast cancer through the extracellular-signal regulated kinase pathway. ( Sun, KW; Yu, K; Yuan, HJ, 2014)
"In order to explore the synergistic mechanisms of combinatorial treatment using curcumin and mitomycin C (MMC) for breast cancer, MCF-7 breast cancer xenografts were conducted to observe the synergistic effect of combinatorial treatment using curcumin and MMC at various dosages."3.80Synergistic effect of combinatorial treatment with curcumin and mitomycin C on the induction of apoptosis of breast cancer cells: a cDNA microarray analysis. ( Chen, QL; Du, J; Lu, YY; Su, SB; Wang, XF; Zhang, H; Zhou, QM, 2014)
"This study was designed to investigate the role of protein kinase C (PKC) and extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in tamoxifen (TAM)-induced apoptosis and drug resistance in human breast cancer cells."3.78Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells. ( Fang, J; Huang, J; Li, C; Li, Z; Tian, F; Wang, N; Xie, F, 2012)
"Reports of the ability of estrogenic agents such as 17beta-estradiol (E2), estriol (E3) and bisphenol A (BPA) to induce micronuclei (MN) in MCF-7 breast cancer cells have prompted us to investigate whether these effects are linked to activation of the estrogen receptor (ER) alpha."3.74Estrogens and genomic instability in human breast cancer cells--involvement of Src/Raf/Erk signaling in micronucleus formation by estrogenic chemicals. ( Kabil, A; Kortenkamp, A; Silva, E, 2008)
"To determine the in vitro effects of simultaneously administered LY29400, PD98059, tamoxifen and eicosapentaenoic acid (EPA) on breast cancer cells, and determine their transcutaneous delivery."3.74In vitro effects on MCF-7 breast cancer cells of signal transduction inhibitor/tamoxifen/eicosapentaenoic acid combinations and their simultaneous delivery across skin. ( Davison, Z; Dutkowski, C; Gee, JM; Heard, CM; Nicholson, RI, 2008)
"Tamoxifen (Tam) is widely used in chemotherapy of breast cancer."3.74Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. ( Härkönen, P; Kallio, A; Zheng, A, 2007)
"In this paper the signal transduction pathways evoked by bradykinin (BK) in MCF-7 breast cancer cells were investigated."3.73Protein kinase C (PKC)-delta/-epsilon mediate the PKC/Akt-dependent phosphorylation of extracellular signal-regulated kinases 1 and 2 in MCF-7 cells stimulated by bradykinin. ( Greco, S; Marsigliante, S; Storelli, C, 2006)
"Despite the success of tamoxifen in treating hormone-responsive breast cancer, its use is limited by the development of resistance to the drug."3.73Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells. ( Kilker, RL; Planas-Silva, MD, 2006)
"Bcl-2 and Bcl-XL expression and apoptosis induction were analyzed in HER-2 gene-amplified (BT474) and nonamplified (ZR 75-1) breast cancer cell lines exposed to trastuzumab, alone or in combination with either Bcl-2/Bcl-XL bispecific antisense oligonucleotides (AS-4625) or the small-molecule Bcl-2 antagonist HA14-1."3.72Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells. ( Bruno, T; Cianciulli, A; Ciuffreda, L; Cognetti, F; Del Bufalo, D; Milella, M; Mottolese, M; Trisciuoglio, D; Zangemeister-Wittke, U; Zupi, G, 2004)
"We previously reported that the PPARgamma agonist troglitazone (TRO) inhibits proliferation and induces apoptosis in human MCF-7 breast carcinoma cells."3.72Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. ( Blaschke, F; Bruemmer, D; Herle, AJ; Hsueh, WA; Law, RE; Yin, F, 2004)
"In this study we have investigated the role of mitogen-induced and stress-activated MAP kinase pathways in the cellular response to taxol, etoposide and ceramide in three different human cancer cell lines: HeLa cervical carcinoma, MCF7 breast cancer and A431 squamous carcinoma cells."3.71The role of MAPK pathways in the action of chemotherapeutic drugs. ( Boldt, S; Kolch, W; Weidle, UH, 2002)
"Anandamide (ANA) inhibits prolactin- and nerve growth factor (NGF)-induced proliferation of human breast cancer cells by decreasing the levels of the 100 kDa prolactin receptor (PRLr) and the high affinity trk NGF receptor, respectively, and by acting via CB(1)-like cannabinoid receptors."3.70Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. ( De Petrocellis, L; Di Marzo, V; Galve-Roperh, I; Guzmán, M; Melck, D; Rueda, D, 1999)
" The pretreatment, intermittent, and chronic dosing schedules of ospemifene activate naive T-cells, modulate antigen-induced tolerance and reduce tumor-associated, pro-inflammatory cytokines, respectively."1.46Repurposing ospemifene for potentiating an antigen-specific immune response. ( DeGregorio, MW; Kao, CJ; Lin, YC; Phong, B; Vang, DP; Wurz, GT, 2017)
"Moreover, exogenous IL-18 enhanced breast cancer cell migration and suppressed the expression of the tight junction proteins claudin-1, claudin-3, claudin-4, and claudin-12 in MCF-7 cells."1.42Interleukin-18 enhances breast cancer cell migration via down-regulation of claudin-12 and induction of the p38 MAPK pathway. ( Bang, SI; Cheon, S; Cho, D; Jung, MK; Kim, D; Kim, HJ; Park, H; Song, SB; Yang, Y, 2015)
"Moreover, the motility of breast cancer cells was detected by wound-healing and transwell experiments."1.40CD44 targets Na(+)/H(+) exchanger 1 to mediate MDA-MB-231 cells' metastasis via the regulation of ERK1/2. ( Chang, G; Li, Q; Lin, Y; Ma, L; Pang, T; Wang, C; Wang, J; Xu, H; Zhang, H; Zhang, Y, 2014)
"More than 70% of breast cancers in women require estrogens for cell proliferation and survival."1.39Retinoic acid impairs estrogen signaling in breast cancer cells by interfering with activation of LSD1 via PKA. ( Abbondanza, C; Avvedimento, EV; Di Santi, A; Migliaccio, A; Ombra, MN; Perillo, B, 2013)
"Metastatic breast cancer cells frequently and ectopically express the transcription factor RUNX2, which normally attenuates proliferation and promotes maturation of osteoblasts."1.36Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. ( Cool, SM; Dobson, JR; Goh, X; Ito, Y; Kwok, HS; Leong, DT; Lian, JB; Lim, J; Nathan, SS; Pereira, BP; Pratap, J; Salto-Tellez, M; Stein, GS; van Wijnen, AJ; Voorhoeve, PM, 2010)
"In human tamoxifen-resistant breast cancer, our results show a significant correlation between Pin1 overexpression and high levels of LC-3."1.36The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer. ( Cho, HG; Choi, HS; Kang, BS; Khanal, P; Lim, SC; Namgoong, GM; Oh, YK; Shim, JH; Yoo, JC, 2010)
"Tamoxifen was below its limit of detection in both Cabosil M5P formulations."1.36In vitro delivery of anti-breast cancer agents directly via the mammary papilla (nipple). ( Davison, Z; Heard, CM; Lee, LM, 2010)
"This study showed that two ER+ human breast carcinoma cell lines derived from MCF-7 (MVLN cells) that have acquired under OH-Tamoxifen selection two distinct phenotypes of endocrine resistance both displayed constitutive activation of the PI3K/Akt and MAPK pathways."1.36Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. ( Ben Larbi, S; Bieche, I; Cohen, PA; Dumontet, C; Ghayad, SE; Vendrell, JA, 2010)
"Human breast cancer MCF-7 cells were exposed to resveratrol (2, 5 and 10 microM)."1.35Resveratrol inhibits heregulin-beta1-mediated matrix metalloproteinase-9 expression and cell invasion in human breast cancer cells. ( Chiang, EP; Sun, YC; Tang, FY, 2008)
"A cohort of 424 human breast tumors was also assessed by immunohistochemistry."1.35Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer. ( Barnes, RO; Chu, JE; Olson, M; Wang, J; Watson, PH; West, NR, 2008)
"Release of VEGF from a breast cancer cell line (T47D) was quantitated by enzyme linked immunosorbent assay (ELISA)."1.34Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells. ( Bingle, L; Corke, KP; Fang, WG; Gong, LH; Shi, YH; Wang, YX, 2007)
" Treatment of cells with a second inhibitor of polyamine biosynthesis, the S-adenosylmethionine decarboxylase (SAMDC) inhibitor SAM486A, also resulted in a dosage dependent decrease in meprin alpha and MMP-7 mRNA."1.33Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells. ( Bond, JS; Manni, A; Matters, GL, 2005)
"To study the role of PKCdelta in thyroid cancer cells, we used a replication-deficient adenovirus (PKCdeltaAdV), to tightly control PKCdelta expression."1.33Activation of protein kinase C delta induces growth arrest in NPA thyroid cancer cells through extracellular signal-regulated kinase mitogen-activated protein kinase. ( Fujii, T; Koike, K; Kuwano, M; Nakamura, AM; Shirouzu, K; Yamana, H; Yokoyama, G, 2006)
"Human breast cancer (MCF-7) cells were incubated with physiological concentrations of l-T(4) or 17beta-estradiol (E(2)) for 15 min to 24 h, and nuclear ERalpha and serine-118-phosphorylated ERalpha were identified by Western blotting."1.32Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. ( Davis, FB; Davis, PJ; Lin, HY; Tang, HY; Zhang, S, 2004)
"In invasive MDA-MB-231 breast cancer cells, transforming growth factor beta-regulated PTHrP synthesis is mediated by an Ets1/Smad3-dependent activation of the PTHrP P3 promoter."1.32Ets2 and protein kinase C epsilon are important regulators of parathyroid hormone-related protein expression in MCF-7 breast cancer cells. ( Braig, M; Dittmer, J; Hauser, CA; Lindemann, RK; Nordheim, A, 2003)
"ERalpha levels in the mouse uterus and breast cancer cells were significantly lower after cotreatment with E plus TCDD than after treatment with E or TCDD alone, and our results indicate that AhR-mediated inhibition of E-induced transactivation is mainly due to limiting levels of ERalpha in cells cotreated with E plus TCDD."1.32The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. ( Abdelrahim, M; Burghardt, R; Safe, S; Saville, B; Stoner, M; Walker, K; Wormke, M, 2003)
"Paclitaxel treatment of parental MCF-7 cells caused a marked inhibition of Raf-1 kinase activity, concomitant with its mobility shift after 18 h exposure."1.32Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells. ( Han, SS; Koh, WS; Lee, M, 2003)
"Human breast cancer cell lines, which express high levels of endogenous Neu receptor, were treated with the anti-Neu antibody, trastuzumab, together with flavopiridol and subject to MTT assay."1.31Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. ( Albanese, C; D'Amico, M; Lee, RJ; Mani, S; Pestell, RG; Wang, C; Wu, K, 2002)
" To determine the level at which MAPK activation enhanced E(2) sensitivity, we examined the dose-response effects of E(2) on several transcriptional readouts, including ERE-reporter activity and the levels of progesterone receptor and pS2."1.31Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. ( Conaway, M; Li, Y; Masamura, S; Santen, RJ; Wang, JP; Yue, W, 2002)
"In human breast tumors that express ET-2, endothelins and ET-RB expressing macrophages often co-localized."1.31Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. ( Balkwill, FR; Grimshaw, MJ; Wilson, JL, 2002)
"Using breast cancer cell lines derived from transgenic mice that overexpress specific oncogene/growth factors in the mammary gland, we show that heregulin but not her2/neu, c-Myc or v-Ha-ras plays a major role in constitutive NF-kappaB activation."1.31Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. ( Bhat-Nakshatri, P; Nakshatri, H; Sweeney, CJ, 2002)
"Here we show that L1 release in AR breast carcinoma cells is mediated by a member of the disintegrin metalloproteinase (ADAM) family of proteinases."1.31Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells. ( Agmon-Levin, N; Altevogt, P; Gutwein, P; Krauss, K; Mechtersheimer, S; Oleszewski, M, 2000)
"We show here that human breast cancer MCF-7 cells, which were prevented from attaching to the substratum and were floating in medium, responded to IGF-I and initiated DNA synthesis."1.31Anchorage-independent activation of mitogen-activated protein kinase through phosphatidylinositol-3 kinase by insulin-like growth factor I. ( Suzuki, K; Takahashi, K, 2000)
"The human breast carcinoma cell line MCF7 and its derivatives, MCF7/HER-2 and MDD2, were used in the study."1.31Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. ( Bacus, SS; Gudkov, AV; Keyomarsi, K; Komarov, AP; Lowe, M; Lyass, L; Seger, R; Yarden, Y; Yung, Y, 2001)
"E2 rapidly activates MAPK in breast cancer cells, and the mechanism for this effect has not been fully identified."1.31Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. ( Adam, L; Bao, Y; Kumar, R; McPherson, RA; Santen, RJ; Shupnik, M; Song, RX, 2002)
"In MCF7 breast cancer cells, mitogen-activated protein (MAP) kinase (i."1.30The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells. ( Alblas, J; Slager-Davidov, R; Steenbergh, PH; Sussenbach, JS; van der Burg, B, 1998)
"In many human breast cancers and cultured cell lines, insulin receptor expression is elevated, and insulin, via its own insulin receptor, can stimulate cell growth."1.30Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase-independent pathway. ( Frasca, F; Giorgino, F; Gliozzo, B; Goldfine, ID; Milazzo, G; Papa, V; Pezzino, V; Scalia, P; Sciacca, L; Sung, CK; Vigneri, R, 1998)
"The AU565 breast carcinoma cell line was used to determine the role of the extracellular-regulated kinase (ERK) pathway in mediating Heregulinbeta1 (HRGbeta1)-induced mammary cell differentiation."1.30Regulation of heregulin beta1-induced differentiation in a human breast carcinoma cell line by the extracellular-regulated kinase (ERK) pathway. ( Davis, M; Hamburger, AW; Lessor, T; Yoo, JY, 1998)
"Microinjection experiments of human mammary cancer-derived cells (MCF-7 and T47D) with cDNA of catalytically inactive Src or anti-Ras antibody prove that Src and Ras are required for oestradiol and progestin-dependent progression of cells through the cell cycle."1.30Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. ( Ametrano, D; Auricchio, F; Barone, MV; Bilancio, A; Castoria, G; Di Domenico, M; Migliaccio, A, 1999)
"Hs578T, a tumor-derived breast cancer cell line that expresses activated Ha-ras, similarly has a high level of secreted and cell-associated IGFBP-3."1.30Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3) in breast cancer cells. ( Baxter, RC; Martin, JL, 1999)
"Exposure of MDA-MB-231 human mammary carcinoma cells to an ionizing radiation dose of 2 Gy results in immediate activation and Tyr phosphorylation of the epidermal growth factor receptor (EGFR)."1.30Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. ( Amir, C; Contessa, JN; Dent, P; Mikkelsen, RB; Reardon, DB; Schmidt-Ullrich, RK; Valerie, K, 1999)

Research

Studies (119)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's17 (14.29)18.2507
2000's72 (60.50)29.6817
2010's29 (24.37)24.3611
2020's1 (0.84)2.80

Authors

AuthorsStudies
Lee, YJ1
Lin, WL1
Chen, NF1
Chuang, SK1
Tseng, TH1
Ren, J1
Wang, Y1
Ware, T1
Iaria, J1
Ten Dijke, P1
Zhu, HJ1
Zhao, Y2
Ge, CC1
Wang, J4
Wu, XX1
Li, XM1
Li, W1
Wang, SS1
Liu, T1
Hou, JZ1
Sun, H1
Fang, D1
Xie, SQ1
Ishay-Ronen, D1
Diepenbruck, M1
Kalathur, RKR1
Sugiyama, N1
Tiede, S1
Ivanek, R1
Bantug, G1
Morini, MF1
Hess, C1
Christofori, G1
Ombra, MN1
Di Santi, A1
Abbondanza, C1
Migliaccio, A2
Avvedimento, EV1
Perillo, B1
Tehan, L1
Taparra, K1
Phelan, S1
Cheng, H1
Meng, J1
Wang, G1
Meng, Y1
Li, Y2
Wei, D1
Fu, C1
Deng, K1
Shen, A1
Wang, H1
Dai, S1
Yuan, HJ1
Sun, KW1
Yu, K1
Chang, G1
Zhang, H4
Zhang, Y1
Wang, C3
Xu, H1
Lin, Y1
Ma, L1
Li, Q1
Pang, T1
Zhou, QM1
Chen, QL1
Du, J1
Wang, XF1
Lu, YY1
Su, SB1
Wang, XG1
Meng, Q1
Qi, FM1
Yang, QF1
Yang, Y1
Cheon, S1
Jung, MK1
Song, SB1
Kim, D2
Kim, HJ2
Park, H1
Bang, SI2
Cho, D1
Huth, HW1
Albarnaz, JD1
Torres, AA1
Bonjardim, CA1
Ropert, C1
Kang, GJ1
Kim, EJ1
Park, MK1
Byun, HJ1
Nam, S1
Lee, H1
Lee, CH1
Shen, P1
Chen, M1
He, M1
Chen, L1
Song, Y1
Xiao, P1
Wan, X1
Dai, F1
Pan, T1
Wang, Q1
Kao, CJ1
Wurz, GT1
Lin, YC1
Vang, DP1
Phong, B1
DeGregorio, MW1
Barnes, RO1
West, NR1
Olson, M1
Chu, JE1
Watson, PH1
Kabil, A1
Silva, E1
Kortenkamp, A1
Davison, Z2
Dutkowski, C1
Gee, JM3
Nicholson, RI3
Heard, CM2
Zhou, X1
Liu, Y1
You, J1
Zhang, X1
Ye, L1
Habashy, HO1
Powe, DG1
Staka, CM1
Rakha, EA1
Ball, G1
Green, AR1
Aleskandarany, M1
Paish, EC1
Douglas Macmillan, R1
Ellis, IO1
Lau, WS1
Chen, WF1
Chan, RY1
Guo, DA1
Wong, MS1
Park, S1
Yoon, SY1
Kim, KE1
Lee, HR1
Hur, DY1
Song, H1
Cho, DH1
Ghayad, SE1
Vendrell, JA1
Ben Larbi, S1
Dumontet, C1
Bieche, I1
Cohen, PA1
No, M1
Choi, EJ1
Kim, IA1
Lee, LM1
Karroum, A1
Mirshahi, P1
Benabbou, N1
Faussat, AM1
Soria, J1
Therwath, A1
Mirshahi, M1
Hatmi, M1
Namgoong, GM1
Khanal, P1
Cho, HG1
Lim, SC1
Oh, YK1
Kang, BS1
Shim, JH2
Yoo, JC1
Choi, HS1
McClaine, RJ1
Marshall, AM1
Wagh, PK1
Waltz, SE1
Leong, DT1
Lim, J1
Goh, X1
Pratap, J1
Pereira, BP1
Kwok, HS1
Nathan, SS1
Dobson, JR1
Lian, JB1
Ito, Y1
Voorhoeve, PM1
Stein, GS1
Salto-Tellez, M1
Cool, SM1
van Wijnen, AJ1
Ibaragi, S1
Shimo, T1
Iwamoto, M1
Hassan, NM1
Kodama, S1
Isowa, S1
Sasaki, A1
Amin, S1
Kumar, A1
Nilchi, L1
Wright, K1
Kozlowski, M1
Chen, J1
Sun, WL1
Wasylyk, B1
Wang, YP1
Zheng, H1
Swamydas, M1
Nguyen, D2
Allen, LD1
Eddy, J1
Dréau, D1
Li, Z1
Wang, N1
Fang, J1
Huang, J1
Tian, F1
Li, C1
Xie, F1
Li, J1
Jia, L1
Zhao, P1
Jiang, Y1
Zhong, S1
Chen, D1
Chen, HW1
Chao, CY1
Lin, LL1
Lu, CY1
Liu, KL1
Lii, CK1
Li, CC1
Yue, W2
Wang, JP2
Conaway, M1
Masamura, S1
Santen, RJ3
Grimshaw, MJ1
Wilson, JL1
Balkwill, FR1
Zell, JA1
Ramakrishnan, R1
Rathinavelu, A1
Boldt, S1
Weidle, UH1
Kolch, W1
Ahola, TM1
Alkio, N1
Manninen, T1
Ylikomi, T1
Wu, K1
D'Amico, M1
Lee, RJ1
Albanese, C1
Pestell, RG1
Mani, S1
Fukazawa, H1
Noguchi, K1
Murakami, Y1
Uehara, Y1
Labriola, L1
Salatino, M1
Proietti, CJ1
Pecci, A1
Coso, OA1
Kornblihtt, AR1
Charreau, EH1
Elizalde, PV1
Knowlden, JM1
Hutcheson, IR1
Jones, HE1
Madden, T1
Harper, ME1
Barrow, D1
Wakeling, AE1
Wormke, M1
Stoner, M1
Saville, B1
Walker, K1
Abdelrahim, M1
Burghardt, R1
Safe, S1
Lindemann, RK1
Braig, M1
Hauser, CA1
Nordheim, A1
Dittmer, J1
Lee, M1
Koh, WS1
Han, SS1
Lin, VC1
Woon, CT1
Aw, SE1
Guo, C1
Kruger, JS1
Reddy, KB1
Tower, GB1
Coon, CI1
Brinckerhoff, CE1
Lu, Y1
Zi, X1
Pollak, M1
Murphy, L1
Cherlet, T1
Adeyinka, A1
Niu, Y1
Snell, L1
Watson, P1
Tang, HY1
Lin, HY1
Zhang, S1
Davis, FB1
Davis, PJ1
Yin, F1
Bruemmer, D1
Blaschke, F1
Hsueh, WA1
Law, RE1
Herle, AJ1
Miglietta, A1
Panno, ML1
Bozzo, F1
Gabriel, L1
Bocca, C1
Milella, M1
Trisciuoglio, D1
Bruno, T1
Ciuffreda, L1
Mottolese, M1
Cianciulli, A1
Cognetti, F1
Zangemeister-Wittke, U1
Del Bufalo, D1
Zupi, G1
Manni, A3
Washington, S2
Mauger, D1
Hackett, DA1
Verderame, MF2
Wen, YJ1
Mancino, A1
Pashov, A1
Whitehead, T1
Stanley, J1
Kieber-Emmons, T1
Weldon, CB1
McKee, A1
Collins-Burow, BM1
Melnik, LI1
Scandurro, AB1
McLachlan, JA1
Burow, ME2
Beckman, BS1
Peyregne, VP1
Kar, S1
Ham, SW1
Wang, M1
Wang, Z1
Carr, BI1
Ostrakhovitch, EA1
Cherian, MG1
Matters, GL1
Bond, JS1
Lester, RD1
Jo, M1
Campana, WM1
Gonias, SL1
Radice, S1
Chiesara, E1
Frigerio, S1
Fumagalli, R1
Parolaro, D1
Rubino, T1
Marabini, L1
Hu, X1
Greco, S1
Storelli, C1
Marsigliante, S1
Normanno, N1
De Luca, A1
Maiello, MR1
Campiglio, M1
Napolitano, M1
Mancino, M1
Carotenuto, A1
Viglietto, G1
Menard, S1
Koike, K1
Fujii, T1
Nakamura, AM1
Yokoyama, G1
Yamana, H1
Kuwano, M1
Shirouzu, K1
Vadgama, JV1
Scuric, Z1
Chakrabarti, R1
Marzo, E1
Shen, D1
Wu, Y1
Lee, TJ1
Lee, JT1
Park, JW1
Kwon, TK1
Kilker, RL1
Planas-Silva, MD1
Zheng, A1
Kallio, A1
Härkönen, P1
Lei, X1
Yang, J1
Nichols, RW1
Sun, LZ1
Hamilton, SR1
Fard, SF1
Paiwand, FF1
Tolg, C1
Veiseh, M1
McCarthy, JB1
Bissell, MJ1
Koropatnick, J1
Turley, EA1
Lin, CW1
Yang, LY1
Shen, SC1
Chen, YC1
Tang, FY1
Chiang, EP1
Sun, YC1
Shi, YH1
Bingle, L1
Gong, LH1
Wang, YX1
Corke, KP1
Fang, WG1
Lauber, SN1
Gooderham, NJ1
Lee, HJ1
Ji, Y1
Paul, S1
Maehr, H1
Uskokovic, M1
Suh, N1
Fortino, V1
Torricelli, C1
Capurro, E1
Sacchi, G1
Valacchi, G1
Maioli, E1
Das, S1
Banerji, A1
Frei, E1
Chatterjee, A1
Hockings, JK1
Degner, SC1
Morgan, SS1
Kemp, MQ1
Romagnolo, DF1
Dufourny, B1
Alblas, J2
van Teeffelen, HA1
van Schaik, FM1
van der Burg, B2
Steenbergh, PH2
Sussenbach, JS2
Slager-Davidov, R1
Jackson, JG1
White, MF1
Yee, D1
Zhou, JN2
Ljungdahl, S1
Shoshan, MC3
Swedenborg, J1
Linder, S3
Fiddes, RJ1
Janes, PW1
Sivertsen, SP1
Sutherland, RL1
Musgrove, EA1
Daly, RJ1
Mueller, E1
Sarraf, P1
Tontonoz, P1
Evans, RM1
Martin, KJ1
Zhang, M1
Fletcher, C1
Singer, S1
Spiegelman, BM1
Gliozzo, B1
Sung, CK1
Scalia, P1
Papa, V1
Frasca, F1
Sciacca, L1
Giorgino, F1
Milazzo, G1
Goldfine, ID1
Vigneri, R1
Pezzino, V1
Lessor, T1
Yoo, JY1
Davis, M1
Hamburger, AW1
Niemann, C1
Brinkmann, V1
Spitzer, E1
Hartmann, G1
Sachs, M1
Naundorf, H1
Birchmeier, W1
Suzuki, N1
Urano, J1
Tamanoi, F1
Castoria, G1
Barone, MV1
Di Domenico, M1
Bilancio, A1
Ametrano, D1
Auricchio, F1
Martin, JL1
Baxter, RC1
Asslan, R1
Pradines, A1
Pratx, C1
Allal, C1
Favre, G1
Le Gaillard, F1
Reardon, DB1
Contessa, JN1
Mikkelsen, RB1
Valerie, K1
Amir, C1
Dent, P1
Schmidt-Ullrich, RK1
Lee, AW1
Nambirajan, S1
Moffat, JG1
Melck, D1
Rueda, D1
Galve-Roperh, I1
De Petrocellis, L1
Guzmán, M1
Di Marzo, V1
Monno, S1
Newman, MV1
Cook, M1
Lowe, WL1
Gingras, S1
Côté, S1
Simard, J1
Lobenhofer, EK1
Huper, G1
Iglehart, JD1
Marks, JR1
Okajima, E1
Thorgeirsson, UP1
Gutwein, P1
Oleszewski, M1
Mechtersheimer, S1
Agmon-Levin, N1
Krauss, K1
Altevogt, P1
Suzuki, K1
Takahashi, K1
Alam, J1
Wicks, C1
Stewart, D1
Gong, P1
Touchard, C1
Otterbein, S1
Choi, AM1
Tou, J1
Seddighzadeh, M2
Kronenwett, U1
Auer, G2
Sten-Linder, M1
Wiman, B1
Vadlamudi, RK1
Adam, L2
Wang, RA1
Mandal, M1
Sahin, A1
Chernoff, J1
Hung, MC1
Kumar, R2
Alaiya, AA1
Jeng, MH1
Eischeid, A1
Hermanto, U1
Zong, CS1
Wang, LH1
Dunn, SE1
Torres, JV1
Oh, JS1
Cykert, DM1
Barrett, JC1
Bacus, SS1
Gudkov, AV1
Lowe, M1
Lyass, L1
Yung, Y1
Komarov, AP1
Keyomarsi, K1
Yarden, Y1
Seger, R1
Song, RX1
McPherson, RA1
Bao, Y1
Shupnik, M1
Yao, J1
Xiong, S1
Klos, K1
Nguyen, N1
Grijalva, R1
Li, P1
Yu, D1
Bhat-Nakshatri, P1
Sweeney, CJ1
Nakshatri, H1
Orlowski, RZ1
Small, GW1
Shi, YY1
Métivier, R1
Gay, FA1
Hübner, MR1
Flouriot, G1
Salbert, G1
Gannon, F1
Kah, O1
Pakdel, F1

Other Studies

119 other studies available for pd 98059 and Breast Neoplasms

ArticleYear
Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
    European journal of medicinal chemistry, 2012, Volume: 56

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Movement; Cell Proliferation; Coumarins; Dose

2012
Reactivation of BMP signaling by suboptimal concentrations of MEK inhibitor and FK506 reduces organ-specific breast cancer metastasis.
    Cancer letters, 2020, 11-28, Volume: 493

    Topics: Animals; Bone Morphogenetic Proteins; Breast Neoplasms; Butadienes; Cell Line, Tumor; Cell Prolifera

2020
MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation.
    Oncology reports, 2017, Volume: 38, Issue:5

    Topics: beta Catenin; Breast Neoplasms; Cell Movement; Cell Nucleolus; Cell Proliferation; ErbB Receptors; F

2017
Gain Fat-Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis.
    Cancer cell, 2019, 01-14, Volume: 35, Issue:1

    Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement;

2019
Retinoic acid impairs estrogen signaling in breast cancer cells by interfering with activation of LSD1 via PKA.
    Biochimica et biophysica acta, 2013, Volume: 1829, Issue:5

    Topics: Breast Neoplasms; Catalytic Domain; Chromatin; Colforsin; Cyclic AMP-Dependent Protein Kinases; Estr

2013
Peroxiredoxin overexpression in MCF-7 breast cancer cells and regulation by cell proliferation and oxidative stress.
    Cancer investigation, 2013, Volume: 31, Issue:6

    Topics: Acetylcysteine; Anthracenes; Antioxidants; Breast Neoplasms; Cell Proliferation; Extracellular Signa

2013
Skp2 regulates subcellular localization of PPARγ by MEK signaling pathways in human breast cancer.
    International journal of molecular sciences, 2013, Aug-09, Volume: 14, Issue:8

    Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; Enzyme Inhibitors; Female; Flavonoids; Humans; MAP K

2013
Leptin promotes the proliferation and migration of human breast cancer through the extracellular-signal regulated kinase pathway.
    Molecular medicine reports, 2014, Volume: 9, Issue:1

    Topics: Animals; Breast Neoplasms; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kin

2014
CD44 targets Na(+)/H(+) exchanger 1 to mediate MDA-MB-231 cells' metastasis via the regulation of ERK1/2.
    British journal of cancer, 2014, Feb-18, Volume: 110, Issue:4

    Topics: Animals; Anti-Arrhythmia Agents; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Cat

2014
Synergistic effect of combinatorial treatment with curcumin and mitomycin C on the induction of apoptosis of breast cancer cells: a cDNA microarray analysis.
    International journal of molecular sciences, 2014, Sep-15, Volume: 15, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Curcumin; Drug Synerg

2014
Blocking TGF-β inhibits breast cancer cell invasiveness via ERK/S100A4 signal.
    European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:24

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Female; Flavonoids; Humans; MAP Kinase Signaling

2014
Interleukin-18 enhances breast cancer cell migration via down-regulation of claudin-12 and induction of the p38 MAPK pathway.
    Biochemical and biophysical research communications, 2015, Apr-10, Volume: 459, Issue:3

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Claudin-1; Claudin-3; Claudin-4; Claudins; Down-R

2015
MEK2 controls the activation of MKK3/MKK6-p38 axis involved in the MDA-MB-231 breast cancer cell survival: Correlation with cyclin D1 expression.
    Cellular signalling, 2016, Volume: 28, Issue:9

    Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Down-R

2016
Novel effects of sphingosylphosphorylcholine on invasion of breast cancer: Involvement of matrix metalloproteinase-3 secretion leading to WNT activation.
    Biochimica et biophysica acta, 2016, Volume: 1862, Issue:9

    Topics: Breast Neoplasms; Caproates; Cell Line, Tumor; Female; Flavonoids; Gene Silencing; Humans; Matrix Me

2016
Inhibition of ERα/ERK/P62 cascades induces "autophagic switch" in the estrogen receptor-positive breast cancer cells exposed to gemcitabine.
    Oncotarget, 2016, Jul-26, Volume: 7, Issue:30

    Topics: Antimetabolites, Antineoplastic; Autophagy; Beclin-1; Breast Neoplasms; Cytoprotection; Deoxycytidin

2016
Repurposing ospemifene for potentiating an antigen-specific immune response.
    Menopause (New York, N.Y.), 2017, Volume: 24, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calmodulin; Cancer Vaccin

2017
Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer.
    Breast cancer research : BCR, 2008, Volume: 10, Issue:3

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cohort Studies; COP9 Signalosome Complex; Enzyme I

2008
Estrogens and genomic instability in human breast cancer cells--involvement of Src/Raf/Erk signaling in micronucleus formation by estrogenic chemicals.
    Carcinogenesis, 2008, Volume: 29, Issue:10

    Topics: Benzhydryl Compounds; Benzo(a)pyrene; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogens; Extr

2008
In vitro effects on MCF-7 breast cancer cells of signal transduction inhibitor/tamoxifen/eicosapentaenoic acid combinations and their simultaneous delivery across skin.
    Pharmaceutical research, 2008, Volume: 25, Issue:11

    Topics: Administration, Cutaneous; Animals; Breast Neoplasms; Cell Line, Tumor; Chromones; Cyclooxygenase 2;

2008
Myosin light-chain kinase contributes to the proliferation and migration of breast cancer cells through cross-talk with activated ERK1/2.
    Cancer letters, 2008, Nov-08, Volume: 270, Issue:2

    Topics: Azepines; beta Catenin; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cycli

2008
Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
    Breast cancer research and treatment, 2010, Volume: 119, Issue:2

    Topics: Adult; Antigens, CD; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carcinoma

2010
Mitogen-activated protein kinase (MAPK) pathway mediates the oestrogen-like activities of ginsenoside Rg1 in human breast cancer (MCF-7) cells.
    British journal of pharmacology, 2009, Volume: 156, Issue:7

    Topics: Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Estrogen Recep

2009
Interleukin-18 induces transferrin expression in breast cancer cell line MCF-7.
    Cancer letters, 2009, Dec-28, Volume: 286, Issue:2

    Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Flavonoids; Flow

2009
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    International journal of cancer, 2010, Jan-15, Volume: 126, Issue:2

    Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Prolife

2010
Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance.
    Cancer biology & therapy, 2009, Volume: 8, Issue:24

    Topics: Antineoplastic Agents; Breast Neoplasms; Butadienes; Cell Cycle; Cell Line, Tumor; Chromones; Dose-R

2009
In vitro delivery of anti-breast cancer agents directly via the mammary papilla (nipple).
    International journal of pharmaceutics, 2010, Mar-15, Volume: 387, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Chromatography, High Pressure Liquid; Chromones; D

2010
Matrix metalloproteinase-9 is required for tubular network formation and migration of resistant breast cancer cells MCF-7 through PKC and ERK1/2 signalling pathways.
    Cancer letters, 2010, Sep-28, Volume: 295, Issue:2

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Flavonoids; Hu

2010
The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer.
    The Journal of biological chemistry, 2010, Jul-30, Volume: 285, Issue:31

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzym

2010
Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.
    Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:8

    Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Surviv

2010
Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility.
    Breast cancer research : BCR, 2010, Volume: 12, Issue:5

    Topics: Adenocarcinoma; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolifera

2010
Parathyroid hormone-related peptide regulates matrix metalloproteinase-13 gene expression in bone metastatic breast cancer cells.
    Anticancer research, 2010, Volume: 30, Issue:12

    Topics: Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; D

2010
Breast cancer cells proliferation is regulated by tyrosine phosphatase SHP1 through c-jun N-terminal kinase and cooperative induction of RFX-1 and AP-4 transcription factors.
    Molecular cancer research : MCR, 2011, Volume: 9, Issue:8

    Topics: Adaptor Protein Complex 4; Adenocarcinoma; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Cell P

2011
c-Jun N-terminal kinase mediates microtubule-depolymerizing agent-induced microtubule depolymerization and G2/M arrest in MCF-7 breast cancer cells.
    Anti-cancer drugs, 2012, Volume: 23, Issue:1

    Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Female; Fl

2012
Progranulin stimulated by LPA promotes the migration of aggressive breast cancer cells.
    Cell communication & adhesion, 2011, Volume: 18, Issue:6

    Topics: Antibodies; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Female; Flavonoids; Focal Adhesion Ki

2011
Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells.
    Oncology reports, 2012, Volume: 27, Issue:6

    Topics: Acetophenones; Antineoplastic Agents, Hormonal; Apoptosis; Benzopyrans; Breast Neoplasms; Carbazoles

2012
Stable knockdown of clusterin by vectorbased RNA interference in a human breast cancer cell line inhibits tumour cell invasion and metastasis.
    The Journal of international medical research, 2012, Volume: 40, Issue:2

    Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Clusterin; Extracell

2012
Inhibition of matrix metalloproteinase-9 expression by docosahexaenoic acid mediated by heme oxygenase 1 in 12-O-tetradecanoylphorbol-13-acetate-induced MCF-7 human breast cancer cells.
    Archives of toxicology, 2013, Volume: 87, Issue:5

    Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinogens; Cell Movement;

2013
Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol.
    Endocrinology, 2002, Volume: 143, Issue:9

    Topics: Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; DNA-Binding Proteins; Dose-Respons

2002
Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors.
    European journal of immunology, 2002, Volume: 32, Issue:9

    Topics: Bacterial Proteins; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Hypoxia; Cell Line; Chemokines

2002
Regulation of mdm2 mRNA expression in human breast tumor-derived GI-101A cells.
    Life sciences, 2002, Oct-04, Volume: 71, Issue:20

    Topics: Alkaloids; Animals; Base Sequence; Benzophenanthridines; Breast Neoplasms; Diethylstilbestrol; DNA P

2002
The role of MAPK pathways in the action of chemotherapeutic drugs.
    Carcinogenesis, 2002, Volume: 23, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Squamous Cell; Cell C

2002
Progestin and G protein-coupled receptor 30 inhibit mitogen-activated protein kinase activity in MCF-7 breast cancer cells.
    Endocrinology, 2002, Volume: 143, Issue:12

    Topics: Breast Neoplasms; Butadienes; Cell Division; DNA, Antisense; Enzyme Inhibitors; Flavonoids; Gene Exp

2002
Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western;

2002
Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:5

    Topics: Animals; Anoikis; Antineoplastic Agents; Breast Neoplasms; Butadienes; Cell Division; Cell Line, Tra

2002
Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
    Molecular and cellular biology, 2003, Volume: 23, Issue:3

    Topics: Animals; Breast Neoplasms; Cell Division; Cell Nucleus; Enzyme Inhibitors; Female; Flavonoids; Genes

2003
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
    Endocrinology, 2003, Volume: 144, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms;

2003
The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes.
    Molecular and cellular biology, 2003, Volume: 23, Issue:6

    Topics: Animals; Breast Neoplasms; Cycloheximide; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Fem

2003
Ets2 and protein kinase C epsilon are important regulators of parathyroid hormone-related protein expression in MCF-7 breast cancer cells.
    The Biochemical journal, 2003, Jun-15, Volume: 372, Issue:Pt 3

    Topics: Base Sequence; Binding Sites; Breast Neoplasms; Cell Line, Transformed; DNA-Binding Proteins; Enzyme

2003
Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells.
    Cancer letters, 2003, Apr-10, Volume: 193, Issue:1

    Topics: Apoptosis; Breast Neoplasms; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neo

2003
Distinct molecular pathways mediate progesterone-induced growth inhibition and focal adhesion.
    Endocrinology, 2003, Volume: 144, Issue:12

    Topics: Antibodies; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cyclin A; Cyclin B; Cyclin B1; Cyclin

2003
Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells.
    Molecular cancer research : MCR, 2003, Volume: 1, Issue:11

    Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Movement; ErbB Receptors; Flavonoids; Gene E

2003
The 2G single nucleotide polymorphism (SNP) in the MMP-1 promoter contributes to high levels of MMP-1 transcription in MCF-7/ADR breast cancer cells.
    Breast cancer research and treatment, 2003, Volume: 82, Issue:2

    Topics: Binding Sites; Breast Neoplasms; Cell Line, Tumor; Collagen Type I; Down-Regulation; Enzyme Inhibito

2003
Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
    Biochemical and biophysical research communications, 2004, Jan-16, Volume: 313, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Antibodies, Monoclonal;

2004
Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Feb-15, Volume: 10, Issue:4

    Topics: Biomarkers, Tumor; Biopsy; Blotting, Western; Breast Neoplasms; Cell Differentiation; Cell Line, Tum

2004
Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor.
    Endocrinology, 2004, Volume: 145, Issue:7

    Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Nucleus; Enzyme Inhibitors; Estradiol; Estro

2004
Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells.
    Oncogene, 2004, Jun-03, Volume: 23, Issue:26

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Cell Cycle; Chromans; Enzyme Inhibito

2004
Insulin can modulate MCF-7 cell response to paclitaxel.
    Cancer letters, 2004, Jun-25, Volume: 209, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Drug

2004
Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; bcl-X P

2004
Cellular mechanisms mediating the anti-invasive properties of the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) in human breast cancer cells.
    Clinical & experimental metastasis, 2004, Volume: 21, Issue:5

    Topics: Breast Neoplasms; Eflornithine; Enzyme Inhibitors; Flavonoids; Hepatocyte Growth Factor; Humans; Mit

2004
Antigen binding of human IgG Fabs mediate ERK-associated proliferation of human breast cancer cells.
    DNA and cell biology, 2005, Volume: 24, Issue:2

    Topics: Amino Acid Sequence; Antigens, Neoplasm; Autoantibodies; Breast Neoplasms; Cell Line, Tumor; Cell Pr

2005
PKC-mediated survival signaling in breast carcinoma cells: a role for MEK1-AP1 signaling.
    International journal of oncology, 2005, Volume: 26, Issue:3

    Topics: Apigenin; Apoptosis; Breast Neoplasms; Cell Survival; Diet; Female; Flavones; Flavonoids; Humans; MA

2005
Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:4

    Topics: Antineoplastic Agents; Biotinylation; Blotting, Western; Breast Neoplasms; Carcinoma, Hepatocellular

2005
Inhibition of extracellular signal regulated kinase (ERK) leads to apoptosis inducing factor (AIF) mediated apoptosis in epithelial breast cancer cells: the lack of effect of ERK in p53 mediated copper induced apoptosis.
    Journal of cellular biochemistry, 2005, Aug-15, Volume: 95, Issue:6

    Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Copper; Enzyme Activation; Epithelial Cells; Extracel

2005
Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells.
    Clinical & experimental metastasis, 2005, Volume: 22, Issue:4

    Topics: Amidines; Antineoplastic Agents; Breast Neoplasms; Down-Regulation; Eflornithine; Enzyme Inhibitors;

2005
Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia.
    The Journal of biological chemistry, 2005, Nov-25, Volume: 280, Issue:47

    Topics: Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Erythropoietin; Female; Flavonoids;

2005
Estrogenic effect of procymidone through activation of MAPK in MCF-7 breast carcinoma cell line.
    Life sciences, 2006, May-01, Volume: 78, Issue:23

    Topics: alpha-Tocopherol; Breast Neoplasms; Bridged Bicyclo Compounds; Cell Line, Tumor; Cell Proliferation;

2006
Interaction between Polyamines and the Mitogen-Activated Protein Kinase Pathway in the Regulation of Cell Cycle Variables in Breast Cancer Cells.
    Cancer research, 2005, Dec-01, Volume: 65, Issue:23

    Topics: Breast Neoplasms; Butadienes; Calcium-Binding Proteins; Cell Cycle; Cell Growth Processes; Cell Line

2005
Protein kinase C (PKC)-delta/-epsilon mediate the PKC/Akt-dependent phosphorylation of extracellular signal-regulated kinases 1 and 2 in MCF-7 cells stimulated by bradykinin.
    The Journal of endocrinology, 2006, Volume: 188, Issue:1

    Topics: Analysis of Variance; Biological Transport; Bradykinin; Bradykinin B1 Receptor Antagonists; Bradykin

2006
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Journal of cellular physiology, 2006, Volume: 207, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Breast Neoplasms; Cell Line, Tumor;

2006
Activation of protein kinase C delta induces growth arrest in NPA thyroid cancer cells through extracellular signal-regulated kinase mitogen-activated protein kinase.
    Thyroid : official journal of the American Thyroid Association, 2006, Volume: 16, Issue:4

    Topics: Adenoviridae; Breast Neoplasms; Carcinoma; Carcinoma, Papillary; Cell Cycle; Cell Line, Tumor; Cycli

2006
Insulin-like growth factor I differentially regulates the expression of HIRF1/hCAF1 and BTG1 genes in human MCF-7 breast cancer cells.
    International journal of molecular medicine, 2006, Volume: 18, Issue:1

    Topics: Amino Acid Sequence; Base Sequence; Blotting, Northern; Breast Neoplasms; Cell Line, Tumor; Chromone

2006
Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation.
    Biochemical and biophysical research communications, 2006, Dec-29, Volume: 351, Issue:4

    Topics: Breast Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Down-Regulation; Drug

2006
Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells.
    Cancer research, 2006, Dec-01, Volume: 66, Issue:23

    Topics: Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Cy

2006
Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen.
    Endocrinology, 2007, Volume: 148, Issue:6

    Topics: Breast Neoplasms; Carcinoma; Cell Death; Cell Line, Tumor; Cell Nucleus; ErbB Receptors; Estrogens;

2007
Abrogation of TGFbeta signaling induces apoptosis through the modulation of MAP kinase pathways in breast cancer cells.
    Experimental cell research, 2007, May-01, Volume: 313, Issue:8

    Topics: Apoptosis; Autocrine Communication; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; Fe

2007
The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells.
    The Journal of biological chemistry, 2007, Jun-01, Volume: 282, Issue:22

    Topics: Antibodies, Monoclonal; Autocrine Communication; Breast Neoplasms; Cell Line, Tumor; Cell Movement;

2007
IGF-I plus E2 induces proliferation via activation of ROS-dependent ERKs and JNKs in human breast carcinoma cells.
    Journal of cellular physiology, 2007, Volume: 212, Issue:3

    Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Acetylcysteine; Anthracenes; Antineoplastic

2007
Resveratrol inhibits heregulin-beta1-mediated matrix metalloproteinase-9 expression and cell invasion in human breast cancer cells.
    The Journal of nutritional biochemistry, 2008, Volume: 19, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Enzyme Activation; Flavonoids

2008
Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells.
    Pathology, 2007, Volume: 39, Issue:4

    Topics: Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Extracellular Signal

2007
The cooked meat derived genotoxic carcinogen 2-amino-3-methylimidazo[4,5-b]pyridine has potent hormone-like activity: mechanistic support for a role in breast cancer.
    Cancer research, 2007, Oct-01, Volume: 67, Issue:19

    Topics: Animals; Breast Neoplasms; Carcinogens; Cell Growth Processes; Estradiol; Flavonoids; Fulvestrant; I

2007
Activation of bone morphogenetic protein signaling by a Gemini vitamin D3 analogue is mediated by Ras/protein kinase C alpha.
    Cancer research, 2007, Dec-15, Volume: 67, Issue:24

    Topics: Bone Morphogenetic Proteins; Breast; Breast Neoplasms; Calcitriol; Carbazoles; Cell Line; Cell Line,

2007
Antiproliferative and survival properties of PMA in MCF-7 breast cancer cell.
    Cancer investigation, 2008, Volume: 26, Issue:1

    Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Act

2008
Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium.
    Life sciences, 2008, Feb-27, Volume: 82, Issue:9-10

    Topics: Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Chromones; Culture Media, Serum-Fr

2008
Involvement of a specificity proteins-binding element in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene.
    Breast cancer research : BCR, 2008, Volume: 10, Issue:2

    Topics: Activating Transcription Factor 2; BRCA1 Protein; Breast Neoplasms; Chromatin Immunoprecipitation; E

2008
Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase.
    The Journal of biological chemistry, 1997, Dec-05, Volume: 272, Issue:49

    Topics: Breast Neoplasms; Cell Division; Chromones; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin

1997
The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells.
    Oncogene, 1998, Jan-08, Volume: 16, Issue:1

    Topics: Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Enzyme Activation; En

1998
Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells.
    The Journal of biological chemistry, 1998, Apr-17, Volume: 273, Issue:16

    Topics: Androstadienes; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Enzyme Inhibitors; F

1998
Activation of tissue-factor gene expression in breast carcinoma cells by stimulation of the RAF-ERK signaling pathway.
    Molecular carcinogenesis, 1998, Volume: 21, Issue:4

    Topics: Base Sequence; Benzoquinones; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Dactin

1998
Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells.
    Oncogene, 1998, May-28, Volume: 16, Issue:21

    Topics: Androstadienes; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Carrier Proteins; Ce

1998
Terminal differentiation of human breast cancer through PPAR gamma.
    Molecular cell, 1998, Volume: 1, Issue:3

    Topics: Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Cell Differentiation; Cell Division;

1998
Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase-independent pathway.
    Journal of cellular biochemistry, 1998, Aug-01, Volume: 70, Issue:2

    Topics: Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cell Line, Transforme

1998
Regulation of heregulin beta1-induced differentiation in a human breast carcinoma cell line by the extracellular-regulated kinase (ERK) pathway.
    Journal of cellular biochemistry, 1998, Sep-15, Volume: 70, Issue:4

    Topics: Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Carrier Proteins; Cell Differentiati

1998
Reconstitution of mammary gland development in vitro: requirement of c-met and c-erbB2 signaling for branching and alveolar morphogenesis.
    The Journal of cell biology, 1998, Oct-19, Volume: 143, Issue:2

    Topics: Androstadienes; Animals; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Cell Adhesi

1998
Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells.
    Proceedings of the National Academy of Sciences of the United States of America, 1998, Dec-22, Volume: 95, Issue:26

    Topics: Alkyl and Aryl Transferases; Androstadienes; Animals; Apoptosis; Breast Neoplasms; Caspase 3; Caspas

1998
Non-transcriptional action of oestradiol and progestin triggers DNA synthesis.
    The EMBO journal, 1999, May-04, Volume: 18, Issue:9

    Topics: 3T3 Cells; Animals; Benzoquinones; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; C

1999
Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3) in breast cancer cells.
    The Journal of biological chemistry, 1999, Jun-04, Volume: 274, Issue:23

    Topics: Apoptosis; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; DNA; Drug

1999
Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells.
    Biochemical and biophysical research communications, 1999, Jul-14, Volume: 260, Issue:3

    Topics: Adenocarcinoma; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Chromones; Epidermal

1999
Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells.
    Oncogene, 1999, Aug-19, Volume: 18, Issue:33

    Topics: Alkyl and Aryl Transferases; Apoptosis; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinas

1999
CSF-1 activates MAPK-dependent and p53-independent pathways to induce growth arrest of hormone-dependent human breast cancer cells.
    Oncogene, 1999, Dec-09, Volume: 18, Issue:52

    Topics: Breast Neoplasms; CDC2-CDC28 Kinases; Cell Division; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2;

1999
Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells.
    FEBS letters, 1999, Dec-17, Volume: 463, Issue:3

    Topics: Arachidonic Acids; Breast Neoplasms; Cell Division; Cell Line; Colforsin; Cyclic AMP; Cyclic AMP-Dep

1999
Insulin-like growth factor I activates c-Jun N-terminal kinase in MCF-7 breast cancer cells.
    Endocrinology, 2000, Volume: 141, Issue:2

    Topics: Breast Neoplasms; Chromones; Enzyme Activation; Enzyme Inhibitors; Female; Flavonoids; Genes, Report

2000
Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells.
    Molecular endocrinology (Baltimore, Md.), 2000, Volume: 14, Issue:2

    Topics: Androstadienes; Breast Neoplasms; Chromones; Enzyme Inhibitors; Female; Flavonoids; Gene Expression

2000
Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis.
    Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 2000, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Androstadienes; Breast Neoplasms; Butadienes; Chromones; Culture Media, Serum-Free;

2000
Different regulation of vascular endothelial growth factor expression by the ERK and p38 kinase pathways in v-ras, v-raf, and v-myc transformed cells.
    Biochemical and biophysical research communications, 2000, Apr-02, Volume: 270, Issue:1

    Topics: Animals; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma; Cell Line; Cell

2000
Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells.
    The Journal of biological chemistry, 2000, May-19, Volume: 275, Issue:20

    Topics: Animals; Antigens, Surface; Breast Neoplasms; Cell Size; CHO Cells; Cricetinae; Disintegrins; Enzyme

2000
Anchorage-independent activation of mitogen-activated protein kinase through phosphatidylinositol-3 kinase by insulin-like growth factor I.
    Biochemical and biophysical research communications, 2000, May-27, Volume: 272, Issue:1

    Topics: Breast Neoplasms; Cell Adhesion; Chromones; DNA, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Fem

2000
Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells. Role of p38 kinase and Nrf2 transcription factor.
    The Journal of biological chemistry, 2000, Sep-08, Volume: 275, Issue:36

    Topics: Animals; Base Sequence; Breast Neoplasms; Cadmium; Cell Line; DNA-Binding Proteins; Enzyme Inhibitor

2000
ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation.
    Clinical & experimental metastasis, 1999, Volume: 17, Issue:8

    Topics: Breast Neoplasms; Cell Division; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme I

1999
Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells.
    The Journal of biological chemistry, 2000, Nov-17, Volume: 275, Issue:46

    Topics: Breast Neoplasms; Cell Adhesion; Cell Division; Cell Movement; Enzyme Activation; Epithelial Cells;

2000
Inhibition of extracellular signal-regulated kinase 1/2 activity of the breast cancer cell line MDA-MB-231 leads to major alterations in the pattern of protein expression.
    Electrophoresis, 2000, Volume: 21, Issue:13

    Topics: Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Electrophoresis, Gel, Two-Dimensi

2000
Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells.
    Breast cancer research and treatment, 2000, Volume: 62, Issue:3

    Topics: Breast Neoplasms; Cell Division; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Estradiol;

2000
Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation.
    Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 2000, Volume: 11, Issue:12

    Topics: Breast Neoplasms; Cell Differentiation; Cell Division; Cell Line; Cell Survival; Down-Regulation; El

2000
Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase.
    Cancer research, 2001, Feb-15, Volume: 61, Issue:4

    Topics: Benzoquinones; Breast Neoplasms; Cell Movement; Chromones; Enzyme Inhibitors; Flavonoids; Gene Expre

2001
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.
    Oncogene, 2001, Jan-11, Volume: 20, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Carcinoma; CDC2-CDC28 Kinas

2001
Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation.
    Molecular endocrinology (Baltimore, Md.), 2002, Volume: 16, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Animals; Binding Sites;

2002
Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells.
    Oncogene, 2001, Dec-06, Volume: 20, Issue:56

    Topics: Breast Neoplasms; Enzyme Activation; Enzyme Inhibitors; Female; Flavonoids; Gene Expression Regulati

2001
Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells.
    Oncogene, 2002, Mar-27, Volume: 21, Issue:13

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Breast Neoplasms; Cell Su

2002
Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis.
    The Journal of biological chemistry, 2002, Aug-02, Volume: 277, Issue:31

    Topics: Apoptosis; Breast Neoplasms; Butadienes; Chymotrypsin; Cysteine Endopeptidases; Cysteine Proteinase

2002
Formation of an hER alpha-COUP-TFI complex enhances hER alpha AF-1 through Ser118 phosphorylation by MAPK.
    The EMBO journal, 2002, Jul-01, Volume: 21, Issue:13

    Topics: Adenocarcinoma; Breast Neoplasms; COUP Transcription Factor I; DNA; DNA-Binding Proteins; Enzyme Inh

2002